Metraipolis › archive › dc_3ca204dcffd9

Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease — Europe PMC PMID:41158984

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41158984
DOI: 10.1016/j.ymgmr.2025.101271
License (as archived): solo-consultazione
Archived: 2026-11-09T06:15:10.529Z
SHA-256 of the archived text: 6eaffb2dcdb3d56494fb34a748c6c94ddbf1a859bc02d5bce6ca0c469ec1dd50
Stable URL of this page: https://metraipolis.com/documento/dc_3ca204dcffd9

How to cite

Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease — Europe PMC PMID:41158984 — Europe PMC (en), https://europepmc.org/article/MED/41158984 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3ca204dcffd9 (Metraipolis archive dc_3ca204dcffd9, sha256 6eaffb2dcdb3d56494fb34a748c6c94ddbf1a859bc02d5bce6ca0c469ec1dd50)

BibTeX

@misc{dc3ca204dcffd9,
  title = {Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease — Europe PMC PMID:41158984},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41158984},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3ca204dcffd9; sha256 6eaffb2dcdb3d56494fb34a748c6c94ddbf1a859bc02d5bce6ca0c469ec1dd50},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41158984. Agents can read the archived copy with the MCP tool read_document.